|
목적 : To evaluate the efficacy and safety of the iStent® glaucoma device in Korean patients with glaucoma.
방법 : Sixteen patients with glaucoma (primary open angle, Juvenile open angle, steroid, pseudoexfoliative, and normal tension glaucoma) who underwent ab interno implantation iStent was enrolled. Patients were assessed following the procedure on days 1 and 7, and months 1 and 3 examinations included visual acuity, intraocular pressure (IOP), number of glaucoma medications, and complications. Wilcoxon rank-test for data with abnormal distribution was used for the analysis of IOP and hypotensive medications at baseline versus days 1 and 7, and months 1 and 3 following the procedure.
결과 : The baseline IOP was 23.31 ± 7.47 (12.5–38) mmHg and significantly decreased in 5.36 ± 7.40 mmHg at 1 day (P = 0.011), -4.60 ± 7.03 mmHg at 1 month (P=0.025), and -7.25 ± 4.96 mmHg at 3 months (P=0.002) except at 1 week (26.60 ± 6.17 mmHg, P=0.550). The number of hypotensive medications was 2.69 ± 0.48 at baseline and reduced to 0.56 ± 0.96 at 3 months (P = 0.04). Although successful IOP reduction were archived in 12 eyes (75%), 4 eyes needed further IOP lowering procedures within 1month. No postoperative complication was encountered except mild hyphema and transient increased IOP.
결론 : The iStent® glaucoma device is a safe and useful adjunctive procedure to lower IOP in glaucoma patients.
|